The role of α-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 29, Issue 5, 2006, Pages 517-523

  Crawford, E David ^a   Kavanagh, Brian D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

1 adrenoreceptor antagonists; Cancer; Lower urinary tract symptoms; Prostate; Radiotherapy

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMIFOSTINE; DOXAZOSIN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PRAZOSIN; SPASMOLYTIC AGENT; TAMSULOSIN; TERAZOSIN;

BLADDER DISEASE; BLADDER IRRITATION; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIZZINESS; DRUG MECHANISM; DYSURIA; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HYPOTENSION; LOWER URINARY TRACT SYMPTOM; MALE; MICTURITION DISORDER; MUSCLE ATROPHY; NOCTURIA; OBSTRUCTIVE UROPATHY; ORTHOSTATIC HYPOTENSION; PERIPHERAL NERVE INJURY; PRACTICE GUIDELINE; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RADIATION INJURY; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; SYMPTOMATOLOGY; SYNCOPE; URETHRITIS; URINARY FREQUENCY; URINARY HESITANCY; URINARY TRACT DISEASE; URINARY URGENCY; URINE RETENTION;

ADRENERGIC ALPHA-ANTAGONISTS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY; URINARY TRACT; UROLOGIC DISEASES;

EID: 33749579470     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000225412.24750.4c     Document Type: Review

References (65)

1. National Comprehensive Cancer Network Treatment Guidelines for Patients. Available at: http://www.Cancer.org/docroot/ETO/ETO_10.asp?siteare_ETO. Accessed. October 31, 2005.
2. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31-40.
3. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002;53:1111-1116.
4. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25-33.
5. Prosnitz RG, Schneider L, Manola J, et al. Tamsulosin palliates radiation-induced urethritis in patients with prostate cancer: results of a pilot study. Int J Radiat Oncol Biol Phys. 1999;45:563-566.
6. Anscher MS, Chen L, Rabbani Z, et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:255-259.
7. Maartense S, Hermans J, Leer JW. Radiation therapy in localized prostate cancer: long-term results and late toxicity. Clin Oncol (R Coll Radiol). 2000;12:222-228.
8. Russo P. Urologic emergencies in the cancer patient. Semin Oncol. 2000;27:284-298.
9. O'Donoghue J. Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm. 2004;19:378-387.
10. Lopez-Beltran A, Luque RJ, Mazzucchelli R, et al. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002;55:641-647.
11. Suresh UR, Smith VJ, Lupton EW, et al. Radiation disease of the urinary tract: histological features of 18 cases. J Clin Pathol. 1993;46:228-231.
12. Sugimura K, Carrington BM, Quivey JM, et al. Postirradiation changes in the pelvis: assessment with MR imaging. Radiology. 1990;175:805-813.
13. Yablon CM, Banner MP, Ramchandani P, et al. Complications of prostate cancer treatment: spectrum of imaging findings. Radiographics. 2004;24(suppl 1):S181-S194.
14. Andersson K-E, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology. 2002;60(suppl 5A):13-21.
15. de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50(suppl):36-52; discussion 53-56.
16. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology. 2003;62(suppl 3A):6-14.
17. Sagnier PP, MacFarlane G, Teillac P, et al. Impact of symptoms of prostatism on level of bother and quality of life of men in the French community. J Urol. 1995;153(Pt 1):669-673.
18. Roehrborn CG, McConnell JD, Saltzman B, et al. Strong (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. Eur Urol. 2002;42:1-6.
19. Welch G, Weinger J, Barry MJ. Quality-of-life impact of lower urinary tract symptoms severity: results from the health professionals follow-up study. Urology. 2002;59:245-250.
20. Mitropoulos D, Anastasiou I, Giannopoulou C, et al. Symptomatic benign prostate hyperplasia: impact on partners' quality of life. Eur Urol. 2002;41:240-244; discussion 244-245.
21. Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer. 2004;101:754-760.
22. Zelefsky MJ, Wallner KE, Ling CC, et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol. 1999;17:517-522.
23. Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44:637-649.
24. Krumholtz JS, Michalski JM, Sundaram CP. Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. J Endourol. 2000;14:371-374.
25. Boyle P, Robertson C, Mazzetta C, et al. The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU Int. 2003;92:575-580.
26. Radiation Therapy Oncology Group. Acute Radiation Morbidity Scoring Criteria. Available at: http://rtog.org/members/toxicity/acute.html#genito. Accessed October 31, 2005.
27. Scarpero HM, Fiske J, Xue X, et al. American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life. Urology. 2003;61:1118-1122.
28. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
29. Mornex F, Pavy JJ, Denekamp J, et al. Scoring system of late effects of radiation on normal tissue: the SOMA-LENT scale. Cancer/Radiother. 1997;1:622-627.
30. Zelefsky MJ, Ginor RX, Fuks Z, et al. Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:567-570.
31. McDonald H, Hux M, Brisson M, et al. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can J Urol. 2004;11:2327-2340.
32. Akduman B, Crawford ED. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 2001;58(suppl 1):49-54.
33. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 1976;48:255-263.
34. Hatano A, Takahashi H, Tamaki M, et al. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728.
35. Hampel C, Dolber PC, Smith MP, et al. Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction. J Urol. 2002;167:1513-1521.
36. 1d-subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85(suppl 2):6-11.
37. Cooper KL, McKiernan JM, Kaplan SA. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia. Drugs. 1999;57:9-17.
38. Lepor H, Laddu A. Terazosin in the treatment of benign prostatic hyperplasia: the United States experience. Br J Urol. 1992;70(suppl 1):2-9.
39. Janknegt RA, Chapple CR. Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups. Eur Urol. 1993;24:319-326.
40. Hoffman BB. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonists. In: Goodman LS, Hardman JG, Limbird LE, et al, eds. Goodman & Gilman's The Pharmacologic Basis of Therapeutics, ed. 10. New York: McGraw Hill; 2001.
41. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol Suppl. 1995;168:7-12.
42. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK). National Diabetes Statistics. Available at: http://diabetes.niddk.nih.gov/ populations/index.htm. Accessed October 31, 2005.
43. American Heart Association. Statistical Fact Sheet: Populations. Older Americans and Cardiovascular Diseases, 2003. Available at: http://www. americanheart.org/downloadable/heart/1105390918119HDSStats2005update.pdf Accessed October 31, 2005.
44. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. Adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
45. Martin DJ. Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36(suppl 1):35-41; discussion 65.
46. Hansen BJ, Nordling J, Mensink HJ, et al. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. Scand J Urol Nephrol Suppl. 1994;157:169-176.
47. Jardin A, Bensadoun H, Delauche-Cavallier MC, et al. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. Lancet. 1991;337:1457-1461.
48. 1-blocker. World J Urol. 2002;19:405-412.
49. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288:201-207.
50. 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). Br J Urol. 1995;76:325-336.
51. Chapple CR, Baert L, Thind P, et al, on behalf of the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). Eur Urol. 1997;32:462-470.
52. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51:892-900.
53. Narayan P, Tewari AA. Second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group. J Urol. 1998;160:1701-1706.
54. Narayan P, Bruskewitz RA. Comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther. 2000;17:287-300.
55. Narayan P, Evans CP, Moon T. Long-term safety and effiacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498-502.
56. Narayan P, O'Leary M, Davidai G. Early efficacy of tamsulosin vs terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245.
57. Merrick GS, Butler WM, Lief JH, et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2000;47:121-128.
58. Lee WR, McQuellon RP, Case LD, et al. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer. J Urol. 1999;162:403-406.
59. Merrick GS, Butler WM, Wallner KE, et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology. 2002;60:650-655.
60. Elshaikh MA, Ulchaker JC, Reddy CA, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys. 2005;62:164-169.
61. Morris DE, Emami B, Mauch PM, et al. Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative. Int J Radiat Oncol Biol Phys. 2005;62:3-19.
62. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:3339-3345.
63. Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys. 2006;64:684-691.
64. Linares LA, Echols D. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial. Semin Oncol. 2003;30(suppl 18):58-62.
65. Menard C, Camphausen K, Muanza T, et al. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results. Semin Oncol. 2003;30(suppl 18):63-67.